EGFR and non-small cell lung carcinoma: Moreover, recent studies have highlighted the role of EGFR-TKIs in the adjuvant treatment of NSCLC [70, 71]; consequently, our study may provide a clue in selecting the EGFR-TKIs with a high concentration in brain in order to prevent a higher incidence of BM in these patients.